Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer

G. Cilenti, L. Tozzi, A. Suriano, A. Tartarone, Giorgio Lelli

Research output: Contribution to journalArticle

Abstract

Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme). The maximum tolerated doses identified were 200 mg/m2 days 1-30 for tegafur and 50 mg days 1-30 for levo-folinate. We obtained 2 partial remissions (7%) and 12 stable disease (45%) in 27 objectively evaluable patients. The main toxicity was gastrointestinal, with no hematologic toxicity. Median time to progression was 4 months (range 2-14), median survival was 10 months (3-30). A median number of 4 cycles (1-13) was administered. The results seem to support the use of this combination in elderly and pretreated patients.

Original languageEnglish
Pages (from-to)402-406
Number of pages5
JournalJournal of Chemotherapy
Volume11
Issue number5
Publication statusPublished - 1999

Fingerprint

Idarubicin
Tegafur
Maximum Tolerated Dose
Breast Neoplasms
Survival

Keywords

  • Advanced breast cancer
  • Breast cancer
  • Idarubicin
  • Levo-folinate
  • Tegafur

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Cilenti, G., Tozzi, L., Suriano, A., Tartarone, A., & Lelli, G. (1999). Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer. Journal of Chemotherapy, 11(5), 402-406.

Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer. / Cilenti, G.; Tozzi, L.; Suriano, A.; Tartarone, A.; Lelli, Giorgio.

In: Journal of Chemotherapy, Vol. 11, No. 5, 1999, p. 402-406.

Research output: Contribution to journalArticle

Cilenti, G, Tozzi, L, Suriano, A, Tartarone, A & Lelli, G 1999, 'Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer', Journal of Chemotherapy, vol. 11, no. 5, pp. 402-406.
Cilenti, G. ; Tozzi, L. ; Suriano, A. ; Tartarone, A. ; Lelli, Giorgio. / Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer. In: Journal of Chemotherapy. 1999 ; Vol. 11, No. 5. pp. 402-406.
@article{06a34cbfda7a406b8ee3a506d975407a,
title = "Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer",
abstract = "Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme). The maximum tolerated doses identified were 200 mg/m2 days 1-30 for tegafur and 50 mg days 1-30 for levo-folinate. We obtained 2 partial remissions (7{\%}) and 12 stable disease (45{\%}) in 27 objectively evaluable patients. The main toxicity was gastrointestinal, with no hematologic toxicity. Median time to progression was 4 months (range 2-14), median survival was 10 months (3-30). A median number of 4 cycles (1-13) was administered. The results seem to support the use of this combination in elderly and pretreated patients.",
keywords = "Advanced breast cancer, Breast cancer, Idarubicin, Levo-folinate, Tegafur",
author = "G. Cilenti and L. Tozzi and A. Suriano and A. Tartarone and Giorgio Lelli",
year = "1999",
language = "English",
volume = "11",
pages = "402--406",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Phase I - II study of oral idarubicin, tegafur and levo-folinate in patients with pretreated advanced breast cancer

AU - Cilenti, G.

AU - Tozzi, L.

AU - Suriano, A.

AU - Tartarone, A.

AU - Lelli, Giorgio

PY - 1999

Y1 - 1999

N2 - Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme). The maximum tolerated doses identified were 200 mg/m2 days 1-30 for tegafur and 50 mg days 1-30 for levo-folinate. We obtained 2 partial remissions (7%) and 12 stable disease (45%) in 27 objectively evaluable patients. The main toxicity was gastrointestinal, with no hematologic toxicity. Median time to progression was 4 months (range 2-14), median survival was 10 months (3-30). A median number of 4 cycles (1-13) was administered. The results seem to support the use of this combination in elderly and pretreated patients.

AB - Thirty patients with pretreated advanced breast cancer were enrolled in a study aimed to establish the maximum tolerated dose and to evaluate the efficacy of oral idarubicin (12 mg/m2/day for 3 days every 4 weeks) with tegafur and levo-folinate (200 mg/m2/day and 50 mg/day, respectively, for a minimum of 6 days, increasing the dose and duration according to a modified Fibonacci scheme). The maximum tolerated doses identified were 200 mg/m2 days 1-30 for tegafur and 50 mg days 1-30 for levo-folinate. We obtained 2 partial remissions (7%) and 12 stable disease (45%) in 27 objectively evaluable patients. The main toxicity was gastrointestinal, with no hematologic toxicity. Median time to progression was 4 months (range 2-14), median survival was 10 months (3-30). A median number of 4 cycles (1-13) was administered. The results seem to support the use of this combination in elderly and pretreated patients.

KW - Advanced breast cancer

KW - Breast cancer

KW - Idarubicin

KW - Levo-folinate

KW - Tegafur

UR - http://www.scopus.com/inward/record.url?scp=0032747537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032747537&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 402

EP - 406

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 5

ER -